Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07243015 · ClinicalTrials.gov registry record
Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers
A clinical trial of Gastric Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT07243015: Recruiting study of Gastric Cancer, sponsored by City of Hope Medical Center.
NCT07243015 is a study of Gastric Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 500 participants, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07243015, a study of Gastric Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific liquid biopsy assay using exosomal microRNAs (exo-miRNAs) to detect MRD and predict distant metastasis before clinical recurrence.
Primary Outcome
Time from surgery to recurrence or death.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST small RNA-seq or array
- DIAGNOSTIC_TEST ENLIGHT Assay
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-01-15 |
| Est. Completion | 2026-06-18 |
What NCT07243015 shows while recruiting
NCT07243015 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 316-participant average among 153 other Gastric Cancer trials with a reported enrollment target (58% higher).
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which small RNA-seq or array is the first listed.
NCT07243015 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07243015 about?
NCT07243015 is a clinical study titled "Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers". Gastric cancer (GC) is a leading cause of cancer-related death worldwide. Even in patients undergoing curative surgery for non-metastatic disease, postoperative recurrence frequently occurs due to undetected minimal residual disease (MRD). This study aims to establish a highly sensitive and specific...
What is the current status of trial NCT07243015?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-01-15. Estimated completion is 2026-06-18.
What conditions does trial NCT07243015 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT07243015?
The interventions under investigation include: small RNA-seq or array (DIAGNOSTIC_TEST), ENLIGHT Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07243015?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07243015 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07243015's enrollment target sits among peer trials
500 24th of 153 higher than 128 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI